Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tailored smoking treatment shows promise for vulnerable patients

NCT ID NCT04590404

Disease control Sponsor: Vanderbilt-Ingram Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a personalized approach to help people quit smoking by matching medication to their nicotine metabolism. 606 adults on Medicaid or Medicare who smoked daily took part. The goal was to see if tailoring treatment improves quit rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

606 people

The number who actually took part.

Started

Nov 2020

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * be 18 years or older * be enrolled in an insurance plan that supports prescription coverage for smoking cessation medication (such as Medicare part D, Medicaid, or private insurance) to facilitate bedside delivery of medications prior to hospital discharge * have a regular provider/PCP * agree to quit or try to quit smoking upon hospital discharge * be a daily smoker when smoking normally during the month prior to entering the hospital * be medically eligible to use varenicline * be medically eligible to use nicotine replacement therapy * have received discharge medication recommendations from a tobacco counselor * agree to take smoking cessation medication (i.e., varenicline OR nicotine replacement therapy) home and consider using it * have a cell phone or landline that can be reached directly (i.e., without transfer) * have a permanent address where they live and can receive mail * estimated life expectancy of at least one year or greater Exclusion Criteria: * insufficient time to perform and complete the enrollment process * barrier to effective communication (including low English proficiency) * not cognitively able to participate in the study * too ill, on hospice, or physically unable to participate in the follow-up process * previously completed the MIST study or is currently enrolled in a quit smoking study that involves a medication-based treatment * estimated life expectancy of less than one year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Smoking are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nicotine dependence Smoking

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Smoking

Contacts and locations

Locations

  • Vanderbilt University Medical Center ViTAL, Vanderbilt Center for Tobacco, Addiction, and Lifestyle General Internal Medicine and Public Health 2525 West End Ave, Suite 450

    Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.